Renaissance Technologies LLC Grows Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Renaissance Technologies LLC boosted its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 28.7% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,582,135 shares of the biotechnology company’s stock after acquiring an additional 575,100 shares during the quarter. Renaissance Technologies LLC owned about 1.11% of ADMA Biologics worth $28,868,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Mesirow Institutional Investment Management Inc. purchased a new position in shares of ADMA Biologics during the 1st quarter valued at approximately $17,221,000. Castleark Management LLC purchased a new position in shares of ADMA Biologics during the 1st quarter valued at approximately $5,400,000. Hillsdale Investment Management Inc. boosted its stake in shares of ADMA Biologics by 41,893.3% during the 1st quarter. Hillsdale Investment Management Inc. now owns 629,900 shares of the biotechnology company’s stock valued at $4,157,000 after buying an additional 628,400 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in shares of ADMA Biologics by 90.7% during the 1st quarter. Russell Investments Group Ltd. now owns 1,169,207 shares of the biotechnology company’s stock valued at $7,717,000 after buying an additional 556,175 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in shares of ADMA Biologics by 152.2% during the 1st quarter. BNP Paribas Financial Markets now owns 732,920 shares of the biotechnology company’s stock valued at $4,837,000 after buying an additional 442,315 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on ADMA. Cantor Fitzgerald increased their target price on ADMA Biologics from $15.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. HC Wainwright increased their target price on ADMA Biologics from $10.00 to $18.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Mizuho increased their target price on ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Thursday, June 20th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, ADMA Biologics presently has an average rating of “Buy” and a consensus target price of $15.50.

ADMA Biologics Stock Performance

ADMA stock opened at $19.74 on Friday. The company has a current ratio of 6.87, a quick ratio of 2.80 and a debt-to-equity ratio of 0.74. The firm has a market cap of $4.58 billion, a P/E ratio of -987.00 and a beta of 0.61. ADMA Biologics, Inc. has a 12-month low of $3.06 and a 12-month high of $19.92. The stock’s 50 day simple moving average is $15.63 and its 200 day simple moving average is $10.83.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.05. The business had revenue of $107.20 million for the quarter, compared to analyst estimates of $86.44 million. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The business’s revenue was up 78.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.02) EPS. As a group, equities research analysts predict that ADMA Biologics, Inc. will post 0.49 EPS for the current year.

Insiders Place Their Bets

In other ADMA Biologics news, CEO Adam S. Grossman sold 236,889 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the sale, the chief executive officer now directly owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other ADMA Biologics news, CEO Adam S. Grossman sold 236,889 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the sale, the chief executive officer now directly owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $16.90, for a total value of $408,135.00. Following the completion of the sale, the chief operating officer now directly owns 449,088 shares in the company, valued at $7,589,587.20. The disclosure for this sale can be found here. Insiders have sold 466,900 shares of company stock valued at $8,224,121 over the last three months. Company insiders own 3.70% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.